Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial

Journal for ImmunoTherapy of Cancer · Published 2026-07-01 · DOI 10.1136/jitc-2026-015351

Free full text

Authors (23)

Maria Gonzalez-Cao, Marta Sisteré-Oró, Teresa Moran, Noemi Reguart, Raquel Cabezon, Andres Aguilar Hernández, Ruth Roman, Miguel A Molina-Vila, Kürşat Birgin, Eva Domenjo-Vila, Gemma Piqué, Miquel Lozano, Paola Charry, Roxana Reyes, Irene Moya, Lluis Cirera, Carlos Esparre, Ana Drozdowskyj, Elizabeth Martínez Pérez, Rafael Rosell, Manel Juan, Andreas Meyerhans, Daniel Benitez-Ribas

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Gonzalez-Cao, M., Sisteré-Oró, M., Moran, T., et al. (2026). Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-015351

Related articles

• TGF-β1 drives neutrophil extracellular traps formation to promote CD8 + T cell exhaustion via the ERK-c-Fos-JunB axis, mediating gastric cancer immunotherapy resistance · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin’s lymphoma · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Systemic immune profiling in hepatocellular carcinoma: navigating etiological heterogeneity and selection bias · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• In situ generation of proinflammatory CAR macrophages via mRNA-TLR agonist co-delivery for triple-negative breast cancer immunotherapy · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• Guarding epithelial integrity: origins of adaptive immunity and cancer immunosurveillance over time and space · Journal for ImmunoTherapy of Cancer · 2026 · Same journal
• UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma · Journal for ImmunoTherapy of Cancer · 2026 · Same journal